As of today (2024-04-23), Corvus Pharmaceuticals's share price is $1.53. Corvus Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.79. Hence, Corvus Pharmaceuticals's Price to Tangible Book Ratio of today is 1.94.
The historical rank and industry rank for Corvus Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
CRVS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.71 Med: 1.77 Max: 2.57
Current: 1.94
During the past 10 years, Corvus Pharmaceuticals's highest Price to Tangible Book Ratio was 2.57. The lowest was 0.71. And the median was 1.77.
CRVS's Price-to-Tangible-Book is ranked better than 66.01% of 1221
companies
in the Biotechnology industry
Industry Median: 2.67
vs CRVS: 1.94
A closely related ratio is called PB Ratio. As of today, Corvus Pharmaceuticals's share price is $1.53. Corvus Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.79. Hence, Corvus Pharmaceuticals's P/B Ratio of today is 1.94.
Corvus Pharmaceuticals Price-to-Tangible-Book Historical Data
The historical data trend for Corvus Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corvus Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corvus Pharmaceuticals Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Corvus Pharmaceuticals Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRVS has been successfully added to your 